Cancer immunotherapy drives implementation science in oncology

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 11, 2014, Pages 3107-3110

  Speiser, Daniel E ^a   Flatz, Lukas ^b  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Cancer; Checkpoint blockade; Immunotherapy; Research development of cancer therapy; T cells; Vaccination

Indexed keywords

DNA VACCINE; HEPATITIS B VACCINE; IPILIMUMAB; RNA VACCINE; SIPULEUCEL T; WART VIRUS VACCINE; CANCER VACCINE;

ANGIOGENESIS; BLOOD VESSEL; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; EDITORIAL; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC SYSTEM; HOST; HUMAN; IMMUNOLOGY; IMMUNOPATHOLOGY; INFLAMMATION; KNOWLEDGE; LIVER CELL CARCINOMA; LYMPH VESSEL; MEDICAL RESEARCH; MELANOMA; NONHUMAN; ONCOLOGY; PATHOPHYSIOLOGY; PROSTATE CANCER; SOLID TUMOR; STROMA; TUMOR GROWTH; UTERINE CERVIX CANCER; VACCINATION; CYTOTOXIC T LYMPHOCYTE; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PROCEDURES; TRANSPLANTATION; TUMOR ASSOCIATED LEUKOCYTE;

CANCER VACCINES; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 84921816107     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/21645515.2014.983000     Document Type: Editorial

References (16)

1. Fridman W-H, Pagès F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306; PMID:22419253; http://dx.doi.org/10.1038/nrc3245
2. Baitsch L, Baumgaertner P, Devêvre E, Raghav SK, Legat A, Barba L, Wieckowski S, Bouzourene H, Deplancke B, Romero P, et al. Exhaustion of tumorspecific CD8C T cells in metastases from melanoma patients. J Clin Invest 2011; 121:2350-60; PMID:21555851; http://dx.doi.org/10.1172/JCI46102
3. Robert-Tissot C, Nguyen LT, Ohashi PS, Speiser DE. Mobilizing and evaluating anticancer T cells: pitfalls and solutions. Expert Rev Vaccines 2013; 12:1325-40; PMID:24127850; http://dx.doi.org/10.1586/14760584.2013.843456
4. Taylor CF, Field D, Sansone S-A, Aerts J, Apweiler R, Ashburner M, Ball CA, Binz P-A, Bogue M, Booth T, et al. Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project. Nat Biotechnol 2008; 26:889-96; PMID:18688244; http://dx.doi.org/10.1038/nbt.1411
5. Lee JA, Spidlen J, Boyce K, Cai J, Crosbie N, Dalphin M, Furlong J, Gasparetto M, Goldberg M, Goralczyk EM, et al. MIFlowCyt: The minimum information about a flow cytometry experiment. Cytometry 2008; 73A:926-30; PMID:18752282; http://dx.doi.org/10.1002/cyto.a.20623
6. Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJM, et al. T cell assays and MIATA: the essential minimum for maximum impact. Immunity 2012; 37:1-2; PMID:22840835; http://dx.doi.org/10.1016/j.immuni.2012.07.010
7. Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Hakansson L, Janetzki S, Kawakami Y, Kleen MV, Ha TO, Lee PP, Maccalli C, et al. Recommendations from the iSBTc-SITC/FDA/NCI workshop on immunotherapy biomarkers. Clin Cancer Res 2011; 17:3064-76; PMID:21558394; http://dx.doi.org/10.1158/1078-0432.CCR-10-2234
8. McShane LM, Altman DG, Sauerbrei W. Identification of clinically useful cancer prognostic factors: what are we missing? JNCI J Natl Cancer Inst 2005; 97:1023-5; PMID:16030294; http://dx.doi.org/10.1093/jnci/dji193
9. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006; 90:297-339; PMID:16730267; http://dx.doi.org/10.1016/S0065-2776(06)90008-X
10. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
11. Riley JL. Combination checkpoint blockade-taking melanoma immunotherapy to the next level. N Engl J Med 2013; 369:187-9; PMID:23724866; http://dx.doi.org/10.1056/NEJMe1305484
12. Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2014; 11:24-37; PMID:24247168; http://dx.doi.org/10.1038/nrclinonc.2013.208
13. Baumgaertner P, Jandus C, Rivals J-P, Derré L, Löovgren T, Baitsch L, Guillaume P, Luescher IF, Berthod G, Matter M, et al. Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells. Int J Cancer 2012; 130:2607-17; PMID:21796616; http://dx.doi.org/10.1002/ijc.26297
14. McAllister SS, Gifford AM, Greiner AL, Kelleher SP, Saelzler MP, Ince TA, Reinhardt F, Harris LN, Hylander BL, Repasky EA, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008; 133:994-1005; PMID:18555776; http://dx.doi.org/10.1016/j.cell.2008.04.045
15. Elkabets M, Gifford AM, Scheel C, Nilsson B, Reinhardt F, Bray M-A, Carpenter AE, Jirströom K, Magnusson K, Ebert BL, et al. Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest 2011; 121:784-99; PMID:21266779; http://dx.doi.org/10.1172/JCI43757
16. El-Sadr WM, Philip NM, Justman J. Letting HIV transform academia - embracing implementation science. N Engl J Med 2014; 370:1679-81; PMID:24785205; http://dx.doi.org/10.1056/NEJMp1314777